<DOC>
	<DOCNO>NCT02066454</DOCNO>
	<brief_summary>To evaluate : - incidence venous thromboembolic event ( VTE ) - incidence hemorrhagic complication , In population patient myeloma treated IMiDs require thromboprophylaxis 6 month , use oral anti-Xa anticoagulant , Apixaban , preventive scheme , 2.5 mg x2/day</brief_summary>
	<brief_title>Evaluation Use Apixaban Prevnetion Thromboembolic Disease Patients With Myeloma Trated With iMiDs</brief_title>
	<detailed_description>MYELAXAT trial multicentre , open trial aim evaluate incidence venous thromboembolic event ( VTE ) incidence hemorrhagic complication . All patient Myeloma treat iMiDs require thromboprophylaxis 6 month , use oral anti-Xa anticoagulant , Apixaban , preventive scheme , 2.5 mg x2/day</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<criteria>Patients ( men/women ) age 18 year All consecutive patient , myeloma , firstline treatment relapse , treat With IMiDs ( MPT , Melphalan Prednisone Thalidomide ; Lenalidomide Dexamethasone ) . AND require prevention venous thromboembolic event Aspirin Low molecular Weight Heparin ( LMWH ) minimum duration 6 month At least , 2/3 patient treat LenalidomideDexamethasone . Written informed consent Patients affiliate French social security system equivalent Patient need curative anticoagulant treatment ( heparin , LMWH , vitamin K antagonist , Dabigatran , Rivaroxaban , Apixaban ) associate disorder ( mechanical valve , atrial fibrillation venous thromboembolic disease previous 6 month ) . Patient need preventive treatment anticoagulant postoperative context Patient need antiplatelet treatment ( Aspirin , Clopidogrel , Prasugrel , Ticagrelor dual antiplatelet therapy ) Patient active bleeding high risk bleeding ( ulcer disease , intracranial bleed previous 6 month , uncontrolled hypertension ) Patient undergone surgical intervention within past 30 day likely expose haemorrhagic risk Active hepatic disease ( hepatitis , cirrhosis ) Severe renal insufficiency ( creatinine clearance use Cockcroft equation &lt; 30 ml/mn ) Known allergic reaction Apixaban Contraindication use anticoagulant treatment Prohibited concomitant treatment inhibitor CYP3A4 Pgp : azole antimycotic agent ( ketoconazole , itraconazole , voriconazole , posaconazole ) , inhibitor HIV protease ( ritonavir , indinavir , nelfinavir , atazanavir , saquinavir ) , specific macrolide antibiotic ( clarithromycine , telithromycine ) antithrombotic treatment : salicylate derivates ( aspirin , product contain aspirin ) , antiplatelet therapy , heparin ( unfractionated heparin , low molecular weight heparin , danaparoide sodique , fondaparinux ) , hirudines , oral anticoagulant ( vitamin K antagonist , rivaroxaban , dabigatran ) Patient AST ALT rate &gt; 3 time upper limit normal Patient Bilirubin rate &gt; 1.5 time upper limit normal Patient Platelets rate &lt; 75 G/l Patient Creatinine Clearance ( Cockcroft ) &lt; 30 ml/mn Incidental find proximal Deep Venous Thrombosis screen ultrasound Patients refuse unable give write consent information Patient unable comply protocol requirement , investigator 's opinion Life expectancy le 6 month Incarcerated patient Pregnancy possibility pregnancy within 6 month Females childbearing potential without reliable contraception Ecog &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>myeloma</keyword>
	<keyword>antiXa anticoagulant</keyword>
	<keyword>venous thromboembolic disease</keyword>
	<keyword>iMiDs</keyword>
</DOC>